Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer | Zendy

Andrew Tutt | Zendy; Judy E. Garber | Zendy; Bella Kaufman | Zendy; Giuseppe Viale | Zendy; Debora Fumagalli | Zendy; Priya Rastogi | Zendy; Richard D. Gelber | Zendy; Evandro de Azambuja | Zendy; Anitra Fielding | Zendy; Judith Balmaña | Zendy; Susan M. Domchek | Zendy; Karen A. Gelmon | Zendy; Simon J. Hollingsworth | Zendy; Larissa A. Korde | Zendy; Barbro Linderholm | Zendy; Hanna Bandos | Zendy; Elżbieta Senkus | Zendy; Jennifer M. Suga | Zendy; Zhimin Shao | Zendy; Andrew W. Pippas | Zendy; Zbigniew Nowecki | Zendy; Tomasz Huzarski | Zendy; Patricia A. Ganz | Zendy; Peter C. Lucas | Zendy; Nigel Baker | Zendy; Sibylle Loibl | Zendy; Robin McConnell | Zendy; Martine Piccart | Zendy; Rita K. Schmutzler | Zendy; Guenther G. Steger | Zendy; Joseph P. Costantino | Zendy; Amal Arahmani | Zendy; Norman Wolmark | Zendy; Eleanor McFadden | Zendy; Vassiliki Karantza | Zendy; Sunil R. Lakhani | Zendy; Greg Yothers | Zendy; Christine Campbell | Zendy; Charles E. Geyer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Author(s) -

Andrew Tutt,

Judy E. Garber,

Bella Kaufman,

Giuseppe Viale,

Debora Fumagalli,

Priya Rastogi,

Richard D. Gelber,

Evandro de Azambuja,

Anitra Fielding,

Judith Balmaña,

Susan M. Domchek,

Karen A. Gelmon,

Simon J. Hollingsworth,

Larissa A. Korde,

Barbro Linderholm,

Hanna Bandos,

Elżbieta Senkus,

Jennifer M. Suga,

Zhimin Shao,

Andrew W. Pippas,

Zbigniew Nowecki,

Tomasz Huzarski,

Patricia A. Ganz,

Peter C. Lucas,

Nigel Baker,

Sibylle Loibl,

Robin McConnell,

Martine Piccart,

Rita K. Schmutzler,

Guenther G. Steger,

Joseph P. Costantino,

Amal Arahmani,

Norman Wolmark,

Eleanor McFadden,

Vassiliki Karantza,

Sunil R. Lakhani,

Greg Yothers,

Christine Campbell,

Charles E. Geyer

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2105215

Subject(s) - olaparib , synthetic lethality , breast cancer , homologous recombination , poly adp ribose polymerase , medicine , brca2 protein , polymerase , germline , cancer research , adjuvant , parp inhibitor , germline mutation , cancer , oncology , mutation , dna repair , biology , genetics , dna , gene

Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with BRCA1 or BRCA2 germline mutation-associated early breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research